Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer
نویسندگان
چکیده
منابع مشابه
Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer
BACKGROUND Pancreatic cancer is a rapidly fatal disease with gemcitabine remaining the first-line therapy. We performed a genotype-phenotype association study to identify biomarkers for predicting gemcitabine treatment outcome. MATERIALS AND METHODS We selected the top 200 single nucleotide polymorphisms (SNPs) identified from our previous genome-wide association study to associate with overa...
متن کاملGemcitabine and Pancreatic Cancer
Manuscript received March 14, 2002; accepted April 3, 2002. The use of chemotherapy with concurrent radiation therapy remains a standard treatment option for patients with unresectable or resected adenocarcinoma of the pancreas. This treatment strategy is based in large part on data from serial Gastrointestinal Tumor Study Group trials that have included 5-fluorouracil. Unfortunately, the major...
متن کاملGemcitabine: progress in the treatment of pancreatic cancer.
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor. Treatment with single-agent gemcitabine achieved clinical benefit and symptoms improvement in 20-30% of patients. While 1-year survival was observed in 2% of 5-fluoroura...
متن کاملAnti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy12
Weekly gemcitabine therapy is the major treatment offered for patients with pancreatic adenocarcinoma cancer; however, relative resistance of tumor cells to chemotherapy, rapid regrowth, and metastasis are the main causes of death within a year. Recently, the daily continuous administration of chemotherapy in low doses--called metronomic chemotherapy (MC)--has been shown to inhibit primary tumo...
متن کاملOptions for the treatment of gemcitabine-resistant advanced pancreatic cancer.
CONTEXT Pancreatic cancer is noteworthy in that the number of patients dying from the disease is roughly equal to the number diagnosed. For more than a decade, gemcitabine has constituted the standard of care for the palliative treatment of the majority of patients who present with metastatic or relapsed disease, although the survival gains are limited. Despite a median survival of less than 6 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacogenetics and Genomics
سال: 2016
ISSN: 1744-6872
DOI: 10.1097/fpc.0000000000000241